AVA6103 is a FAP-enabled pre|CISION®peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity

Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Francis Wilson, Michelle Morrow